These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26104996)

  • 21. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
    Westerman EM; Heijerman HG; Frijlink HW
    Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cystic fibrosis in the modern therapeutic era: Give the shower a thought!
    Le Pennec D; Baravalle-Einaudi M; Dupont C; Vecellio L; Dubus JC;
    J Cyst Fibros; 2019 Nov; 18(6):e56-e57. PubMed ID: 30904464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro evaluation of efficacy of 5 methods of disinfection on mouthpieces and facemasks contaminated by strains of cystic fibrosis patients.
    Reychler G; Aarab K; Van Ossel C; Gigi J; Simon A; Leal T; Lebecque P
    J Cyst Fibros; 2005 Sep; 4(3):183-7. PubMed ID: 16046195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects.
    Lenney W; Edenborough F; Kho P; Kovarik JM
    J Cyst Fibros; 2011 Jan; 10(1):9-14. PubMed ID: 20884302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiological contamination of nebulizers used by cystic fibrosis patients: an underestimated problem.
    Riquena B; Monte LFV; Lopes AJ; Silva-Filho LVRFD; Damaceno N; Aquino EDS; Marostica PJC; Ribeiro JD
    J Bras Pneumol; 2019 May; 45(3):e20170351. PubMed ID: 31166553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of nebulised antibiotic delivery in cystic fibrosis.
    Wilson D; Burniston M; Moya E; Parkin A; Smye S; Robinson P; Littlewood J
    Arch Dis Child; 1999 Apr; 80(4):348-52. PubMed ID: 10086942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhaled therapies in cystic fibrosis].
    Dubus JC; Ravilly S
    Rev Mal Respir; 2008 Oct; 25(8):989-98. PubMed ID: 18971805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of Staphylococcus aureus (MSSA and MRSA) to drying: implications for nebulizer hygiene in patients with cystic fibrosis.
    Moore JE; Millar BC
    J Hosp Infect; 2020 Jun; 105(2):366-367. PubMed ID: 32298736
    [No Abstract]   [Full Text] [Related]  

  • 29. Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.
    Thomas SH; O'Doherty MJ; Graham A; Page CJ; Blower P; Geddes DM; Nunan TO
    Thorax; 1991 Oct; 46(10):717-21. PubMed ID: 1750018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thinking inside the box: nebulizer care, safe storage, and risk of infection in cystic fibrosis.
    Alexander L; Carson J; McCaughan J; Moore JE; Millar BC
    J Bras Pneumol; 2020 Apr; 46(2):e20190226. PubMed ID: 32294716
    [No Abstract]   [Full Text] [Related]  

  • 31. Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients.
    Buttini F; Rossi I; Di Cuia M; Rossi A; Colombo G; Elviri L; Sonvico F; Balducci AG
    Int J Pharm; 2016 Apr; 502(1-2):242-8. PubMed ID: 26854429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of hypochlorite-based disinfection on bacterial contamination of cystic fibrosis patients' home-nebulisers.
    Reychler G; Leonard A; Van Ossel C; Godding V; Gigi J; Simon A; Lebecque P
    J Hosp Infect; 2009 Aug; 72(4):351-7. PubMed ID: 19596489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers.
    Della Zuana A; Garcia Dde O; Juliani RC; Silva Filho LV
    J Bras Pneumol; 2014; 40(2):119-27. PubMed ID: 24831395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to nebulised antibiotics in cystic fibrosis.
    Latchford G; Duff A; Quinn J; Conway S; Conner M
    Patient Educ Couns; 2009 Apr; 75(1):141-4. PubMed ID: 18952395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of selective media for the isolation of yeasts and filamentous fungi from the sputum of adult patients with cystic fibrosis (CF).
    Nagano Y; Millar BC; Goldsmith CE; Walker JM; Elborn JS; Rendall J; Moore JE
    J Cyst Fibros; 2008 Nov; 7(6):566-72. PubMed ID: 18723404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
    Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
    Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhaled antibiotics: dry or wet?
    Tiddens HA; Bos AC; Mouton JW; Devadason S; Janssens HM
    Eur Respir J; 2014 Nov; 44(5):1308-18. PubMed ID: 25323242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin.
    Vecellio L; Abdelrahim ME; Montharu J; Galle J; Diot P; Dubus JC
    J Cyst Fibros; 2011 Mar; 10(2):86-92. PubMed ID: 21075063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Placebo inhaler devices and infection risks.
    Weller T
    Nurs Times; 2005 Oct 18-24; 101(42):50. PubMed ID: 16259203
    [No Abstract]   [Full Text] [Related]  

  • 40. A national survey of nebuliser use.
    Childs HJ; Dezateux CA
    Arch Dis Child; 1991 Nov; 66(11):1351-3. PubMed ID: 1755652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.